As Europe accelerates efforts to fortify its pharmaceutical supply chain, the proposed Critical Medicines Act (CMA) is emerging as a defining policy shift that could reshape global medicine flows. For India—one of the world’s most trusted suppliers of generics, APIs, biosimilars and essential therapies—the CMA represents not just an external regulatory update, but a high-value strategic opportunity.

The European Council’s recent endorsement of the CMA signals the EU’s intent to mitigate drug shortages, diversify suppliers, and reinforce domestic manufacturing capacity. While the legislation is rooted in Europe’s internal resilience agenda, its global ripple effects position India’s pharmaceutical ecosystem to play an even greater role in securing the world’s essential medicine supply.

Why the CMA Matters: Europe Seeks Resilience, Reliability & Diversification

Europe has been grappling with recurring shortages of critical medicines—from antibiotics to insulin—which intensified post-pandemic. The CMA aims to address these challenges through five major pillars, including:

• Diversifying global supply chains
• Prioritising resilience criteria over price
• Strengthening joint procurement models
• Enhancing visibility on contingency stocks
• Incentivising local production and innovation

The move is part of a broader trend, mirrored by the U.S., to reduce dependency on concentrated supply sources and bring transparency to essential medicine availability.

A Window of Opportunity for Indian Pharma

1. Diversification Push Strengthens India as a Preferred Supplier

The EU’s heavy reliance on China for APIs and intermediates is a longstanding risk. The CMA’s call to diversify sourcing aligns directly with India’s strengths:

• Robust API manufacturing capabilities
• Deep generics expertise
• EMA-compliant plants and global regulatory experience

This positions India as a natural, reliable diversification partner for critical medicine supplies.

2. A Stronger Case for Indian Firms in Joint EU Procurement

The Act’s emphasis on collaborative procurement models favours companies that offer:

• Proven scale
• Consistent quality
• Reliable delivery performance

Large Indian manufacturers—Sun Pharma, Dr. Reddy’s, Cipla, Lupin, Aurobindo—already meet these conditions. The shift could open doors to EU-wide procurement contracts, rather than fragmented country-level tenders.

3. Rise of “Resilience Over Price” Benefits Indian Capabilities

For the first time, the EU is urging member states to prioritise resilience, supply security, and risk mitigation over low-cost bids during procurement.

Indian companies that demonstrate:

• Multi-site manufacturing
• Diversified supply networks
• Strong regulatory track records
• Mitigation planning

…stand to benefit significantly, moving the competition away from commoditised price wars.

4. Growing Shortage-Prevention Measures Will Increase API Demand

Despite ambitions for onshore production, Europe will take time to scale capacity. During this transition, the continent will require:

• Higher API imports
• Stable finished dosage supplies
• Assurance of uninterrupted availability

As the world’s third-largest API manufacturer, India is uniquely positioned to meet this immediate requirement.

5. Strong Alignment With India’s Own Policy Momentum

The CMA’s objectives mirror India’s ongoing national initiatives:

• PLI schemes for APIs, KSMs, formulations and medtech
• PRIP to stimulate biopharma R&D
• Make in India, strengthening domestic capabilities
• Investments in quality upgrades and shortage monitoring

These synergies create favourable conditions for bilateral cooperation, manufacturing partnerships and regulatory harmonisation.

6. Boost to India–EU Co-Innovation & Manufacturing Collaboration

Europe’s roadmap emphasises modernising manufacturing, adopting advanced technologies and strengthening R&D capacities. 

This aligns perfectly with India’s strengths in biosimilars, complex generics, vaccine manufacturing, large-scale biologics and CDMO/CMO partnerships. 

Joint ventures, co-development models, and EU-funded innovation projects are likely to rise, pulling Indian companies deeper into Europe’s strategic reshoring and resilience agenda.

Caution: Europe’s Local Manufacturing Ambitions Will Create Competition

The EU will also create incentives to produce more within its borders. However, high cost structures, labour shortages, long facility timelines and limited API ecosystem mean that Europe will continue to depend on India for the foreseeable future, especially for high-volume and essential therapeutic classes.

Strategic Outlook: India’s Opportunity to Cement Its Position as a Global Pharma Backbone

The CMA is ultimately an inflexion point for India’s pharmaceutical industry. It reinforces India’s reputation as a trusted global supplier, a resilient manufacturing base and a partner of choice for critical medicine security. 

For Indian pharma leaders, the moment calls for proactive engagement:

• Strengthening EMA-compliance and risk frameworks
• Investing in multi-site supply resilience
• Building EU partnerships across procurement, R&D and manufacturing
• Positioning India as a stable pillar in global medicine continuity

Also read: Top Insights on India from the WHO Global TB Report 2025

A Policy Shift That Strengthens India’s Global Influence

While the EU’s Critical Medicines Act is designed to secure Europe’s internal supply chain, it inadvertently unlocks significant global opportunity.
For India, this is a chance to expand exports, win larger procurement deals, collaborate on innovation, strengthen diplomatic and trade leverage and position the country as a cornerstone of global drug security. 

In an era where medicine resilience is becoming a geopolitical priority, India is uniquely poised to lead—and the CMA only accelerates that trajectory.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official policy or views of any organisation. The content is intended for informational and educational purposes only and should not be construed as medical advice.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!